Amlodipine increases endothelial nitric oxide by dual mechanisms

Pharmacology

Volumn 70, Issue 1, 2004, Pages 39-45

  Berkels, Reinhard ^a   Taubert, Dirk ^a   Bartels, Henning ^a   Breitenbach, Thomas ^a   Klaus, Wolfgang ^a   Roesen, Renate ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Amlodipine; Antioxidative properties; Calcium antagonist; Endothelium; Nitric oxide; Reactive oxygen species

Indexed keywords

AMLODIPINE; CYCLIC GMP; DIMYRISTOYLPHOSPHATIDYLCHOLINE; HYPOXANTHINE; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; XANTHINE OXIDASE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; AORTA; ARTERY ENDOTHELIUM; ARTICLE; ASSAY; BIOAVAILABILITY; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; DRUG MECHANISM; HALF LIFE TIME; LONG TERM EXPOSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWINE;

AMLODIPINE; ANIMALS; ANTIOXIDANTS; AORTA; CELLS, CULTURED; CORONARY VESSELS; CYCLIC GMP; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; NITRITES; OMEGA-N-METHYLARGININE; REACTIVE OXYGEN SPECIES; SUPEROXIDES; SWINE; UP-REGULATION; XANTHINE OXIDASE;

EID: 0345059931     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074241     Document Type: Article

References (45)

1. Frishman WH: Current status of calcium channel blockers. Curr Probl Cardiol 1994;19:637-688.
2. Tsien RW, Hess P, McCleskey EW, Rosenberg RL: Calcium channels: Mechanisms of selectivity, permeation, and block. Annu Rev Biophys Biophys Chem 1987;16:265-290.
3. 2+ channel antagonists. Trends Pharmacol Sci 1992;13:256-262.
4. Berkels R, Roesen R, Dhein S, Fricke U, Klaus W: Dihydropyridine calcium antagonist induced modulation of endothelial function - a review. Cardiovasc Drug Rev 1999;17:179-186.
5. Adams DJ, Barakeh J, Laskey R, Van Breemen C: Ion channels and regulation of intracellular calcium in vascular endothelial cells. FASEB J 1989;3:2389-2400.
6. Colden-Stanfield M, Schilling WP, Ritchie AK, Eskin SG, Navarro LT, Kunze DL: Bradykinin-induced increases in cytosolic calcium and ionic currents in cultured bovine aortic endothelial cells. Circ Res 1987;61:632-640.
7. Berkels R, Egink G, Marsen TA, Bartels H, Roesen R, Klaus W: Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension 2001;37:240-245.
8. i and NO in endothelial cells. J Cardiovasc Pharmacol Ther 1999;4:175-181.
9. Dhein S, Zhao Y, Simsek S, Salameh A, Klaus W: Actions of 1,4-dihydropyridines in isolated mesenteric vascular beds. J Cardiovasc Pharmacol 1995;26:784-791.
10. Ding Y, Vaziri ND: Calcium channel blockade enhances nitric oxide synthase expression by cultured endothelial cells. Hypertension 1998;32:718-723.
11. Godfraind T, Salomone S: Calcium antagonists and endothelial function: Focus on nitric oxide and endothelin. Cardiovasc Drugs Ther 1996;10:439-446.
12. Salomone S, Silva CL, Morel N, Godfraind T: Facilitation of the vasorelaxant action of calcium antagonists by basal nitric oxide in depolarized artery. Naunyn Schmiedebergs Arch Pharmacol 1996;354:505-512.
13. Verhaar MC, Honing ML, van Dam T, Zwart M, Koomans HA, Kastelein JJ, Rabelink TJ: Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc Res 1999;42:752-760.
14. Zhang X, Hintze TH: Amlodipine releases nitric oxide from canine coronary microvessels: An unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998;97:576-580.
15. Zhang XP, Loke KE, Mital S, Chahwala S, Hintze TH: Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the r+ enantiomer of amlodipine. J Cardiovasc Pharmacol 2002;39:208-214.
16. Gunther J, Dhein S, Rosen R, Klaus W, Fricke U: Nitric oxide (EDRF) enhances the vasorelaxing effect of nitrendipine in various isolated arteries. Basic Res Cardiol 1992;87:452-460.
17. Mason RP: Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: Review of the evidence. Atherosclerosis 2002;165:191-199.
18. Mason R: Atheroprotective effects of long-acting dihydropyridine-type calcium channel blockers: Evidence from clinical trials and basic scientific research. Cerebrovasc Dis 2003;16(suppl 3):11-17.
19. Li H, Forstermann U: Structure-activity relationship of staurosporine analogs in regulating expression of endothelial nitric-oxide synthase gene. Mol Pharmacol 2000;57:427-435.
20. Tsukahara H, Gordienko DV, Goligorsky MS: Continuous monitoring of nitric oxide release from human umbilical vein endothelial cells. Biochem Biophys Res Commun 1993;193:722-729.
21. Berkels R, Purol-Schnabel S, Roesen R: A new method to measure nitrate/nitrite with a NO-sensitive electrode. J Appl Physiol 2001;90:317-320.
22. Trevithick JR, Dzialoszynski T: A new technique for enhancing luminol luminescent detection of free radicals and reactive oxygen species. Biochem Mol Biol Int 1994;33:1179-1190.
23. Tesfamariam B, Cohen RA: Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992;263(2 Pt 2):H321-H326.
24. Du X, Stockklauser-Färber K, Rösen P: Generation of reactive oxygen intermediates, activation of NF-KB, and induction of apoptosis in human endothelial cells by glucose: Role of nitric oxide synthase? Free Radic Biol Med 1999;27:252-263.
25. 2+/EDRF signaling are due to generation of superoxide anions. Diabetes 1996;45:1386-1395.
26. Berkels R, Roesen R, Bartels H, Purol-Schnabel S, Kirmiziguel I, Farmer H, Born GV, Klaus W: Nisoldipine increases the bioavailability of endothelial NO. Naunyn Schmiedebergs Arch Pharmacol 2001;364:110-116.
27. Xu B, Xiao-hong L, Lin G, Queen L, Ferro A: Amlodipine, but not verapamil or nifedipine, dilates rabbit femoral artery largely through a nitric oxide- and kinin-dependent mechanism. Br J Pharmacol 2002;136:375-382.
28. Kobayashi N, Yanaka H, Tojo A, Kobayashi K, Matsuoka H: Effects of amlodipine on nitric oxide synthase mRNA expression and coronary microcirculation in prolonged nitric oxide blockade-induced hypertensive rats. J Cardiovasc Pharmacol 1999;34:173-181.
29. Weglicki WB, Mak IT, Dickens BF, Kramer JH: Beta-blockers, calcium channel blockers and the sulfhydryl-ACE inhibitors demonstrate protection against free-radical-mediated injury of cardiovascular cells and membranes. Rev Port Cardiol 1992;11:1009-1011.
30. Mak IT, Weglicki WB: Antioxidant activity of calcium channel blocking drugs. Methods Enzymol 1994;234:620-630.
31. Mak IT, Zhang J, Weglicki WB: Cytoprotective properties of nisoldipine and amlodipine against oxidative endothelial cell injury. Ann NY Acad Sci 2000;899:403-406.
32. Mason RP, Mak IT, Trumbore MW, Mason PE: Antioxidant properties of calcium antagonists related to membrane biophysical interactions. Am J Cardiol 1999;84:16L-22L.
33. Mason RP, Walter MF, Trumbore MW, Olmstead EG Jr, Mason PE: Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 1999;31:275-281.
34. Turgan N, Habif S, Kabaroglu CG, Mutaf I, Ozmen D, Bayindir O, Uysal A: Effects of the calcium channel blocker amlodipine on serum and aortic cholesterol, lipid peroxidation, antioxidant status and aortic histology in cholesterol-fed rabbits. J Biomed Sci 2003;10:65-72.
35. Berkels R, Bertsch A, Breitenbach T, Klaus W: The calcium antagonist nifedipine stimulates endothelial NO release in therapeutical concentrations. Pharm Pharmacol Lett 1996;6:75-78.
36. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 2000;86:494-501.
37. Meyer JW, Schmitt ME: A central role for the endothelial NADPH oxidase in atherosclerosis. FEBS Lett 2000;472:1-4.
38. Zhang H, Schmeisser A, Garlichs CD, Plotze K, Damme U, Mugge A, Daniel WG: Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: Role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res 1999;44:215-222.
39. Rosen P, Du X, Tschope D: Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: Prevention by alpha-tocopherol? Mol Cell Biochem 1998;188:103-111.
40. Du XL, Sui GZ, Stockklauser-Farber K, Weiss J, Zink S, Schwippert B, Wu QX, Tschope D, Rosen P: Introduction of apoptosis by high proinsulin and glucose in cultured human umbilical vein endothelial cells is mediated by reactive oxygen species [see comments]. Diabetologia 1998;41:249-256.
41. Tarpey MM, White CR, Suarez E, Richardson G, Radi R, Freeman BA: Chemiluminescent detection of oxidants in vascular tissue: Lucigenin but not coelenterazine enhances superoxide formation. Circ Res 1999;84:1203-1211.
42. Skatchkov MP, Sperling D, Hink U, Mulsch A, Harrison DG, Sindermann I, Meinertz T, Munzel T: Validation of lucigenin as a chemiluminescent probe to monitor vascular superoxide as well as basal vascular nitric oxide production. Biochem Biophys Res Commun 1999;254:319-324.
43. Thaulow E, Jorgensen B: Results and clinical implications of the CAPARES trial. Can J Cardiol 2000;16Suppl D:8D-11D.
44. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000;102:1503-1510.
45. Koshiyama H, Tanaka S, Minamikawa J: Effect of calcium channel blocker amlodipine on the intimal-medial thickness of carotid arterial wall in type 2 diabetes. J Cardiovasc Pharmacol 1999;33:894-896.